Drug Profile
Research programme: tuberculosis therapies - GlaxoSmithKline/Global Alliance for TB Drug Development
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Global Alliance for TB Drug Development
- Developer Global Alliance for TB Drug Development; GSK
- Class
- Mechanism of Action Acyltransferase inhibitors; DNA gyrase inhibitors; Peptide deformylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in Spain
- 25 Jan 2008 GlaxoSmithKline and the Global Alliance for TB Drug Development extend their collaboration for a further three years
- 25 Jan 2008 Early research is ongoing in Spain